跳到正文
原文
STAT 主站· Elaine Chen·· 2026-10-08AI 评分31

罗氏超越授权模式,与中国生物科技公司Defand Therapeutics合作开发新药

STAT+: Roche goes beyond licensing in deal with Chinese biotech

AI 导读

罗氏与中国初创企业Defand Therapeutics达成合作,共同发现新药。近年药企纷纷涌向中国授权引进现有候选药物,罗氏此次采取了不同以往的新合作模式。

正文

DOJ signals it will start scrutinizing drugmakers, PhrMA sues Trump administration, and more biotech news

gantenerumab Alzheimer's disease Roche
Sebastien Bozon/AFP via Getty Images

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Let’s get straight to the news.

The need-to-know this morning

Roche goes beyond licensing in deal with Chinese biotech

Over the past few years, pharma companies have flocked to China to license existing drug candidates. Roche is taking a new approach, partnering with Chinese startup Defand Therapeutics to discover new medicines.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

来源:STAT 主站 · statnews.com